2023-09-14 23:00:23
The pharmaceutical company Johnson & Johnson was created in the United States in 1887.
Within its area of technological innovation it focuses on the development of medicines for Oncology, Immunology, Neurosciences, Cardiovascular Diseases, Pulmonary Hypertension and Retina.
In 2017, it acquired the Swiss company Actelion for $30 billion, considered the largest acquisition of that decade in the pharmaceutical sector.
Within the pharmaceutical industry there is a company that has been in existence for 135 years and is Johnson & Johnson. During this period, it has developed various health care products and has also faced multiple problems. One of the biggest was caused by its line of baby powders, which was accused of containing carcinogenic elements and even caused millions in losses.
Now, with the mentality that it is always necessary to reinvent oneself to survive, important announcements were made today. On the one hand, the company’s two business segments will now be more connected to the brand. Over time, Janssen, the company’s pharmaceutical segment, will become Johnson & Johnson Innovative Medicine. While medical technology will continue as Johnson & Johnson MedTech.
Development of new drugs
Within this second area, drugs and treatments focused on Oncology, Immunology, Neurosciences, Cardiovascular Diseases, Pulmonary Hypertension and Retina.
Johnson & Johnson is signing off on a new logo. The health care giant says it will replace the well-known signature script it has used since 1887 with a new, modern look.
— The Associated Press (@AP) September 14, 2023
New visual image
Although it is not the only change in the company because it was also announced that it will have a new brand identity. This is a historic event because for the first time in more than a century it will have a change in its visual identity.
Logo. The new logo is modernized for this next chapter. Each letter is drawn with a pencil stroke, creating a contrast that offers a sense of unpredictability and humanity. The company will adopt both long-form and short-form versions of the logo, expanding and building more equity around a short-form “J&J” to appear in a more pleasing and contemporary way, especially on digital interfaces. The brand will also be displayed in motion and will respond to different environments.
Color. Johnson & Johnson will continue to leverage the color red, leaning toward a fresh, bright and contemporary color that speaks to the ability to urgently respond to health challenges, evolve with the times and set the pace.
Ampersand (“&”). The new ampersand captures a human and personable nature. It is now presented as a symbol that can be recognized globally and represents the openness of the brand, as well as the connections that bring the company’s purpose to life.
Art direction. Elements in the art direction style, including illustration, photography and more, have been designed to spark energy, optimism and inclusivity, while offering a unique and distinctive approach to healthcare.
“Our J&J brand identity communicates our bold approach to innovation in healthcare, while staying true to the care we have for our patients around the world,” said Vanessa Broadhurst, Executive Vice President of Global Corporate Affairs. .
Also read:
FDA authorizes the booster doses of Moderna and J&, now what should Cofepris do?
J&J must pay a million-dollar fine for “promoting” the opioid crisis
Bad news! HIV vaccine stops clinical trials due to low efficacy
#Johnson #Johnson #logo #time #century